Cargando...
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR(1,2,3)) and 5 (SSTR(5)). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly tha...
Gardado en:
| Publicado en: | Endocr Relat Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4643672/ https://ncbi.nlm.nih.gov/pubmed/25376618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-14-0360 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|